A re-examination of the MDM2/p53 interaction leads to revised design criteria for novel inhibitors.
The general model of epitope-type MDM2 inhibitor was developed based on the structural information on the complexes between MDM2 and various low molecular weight ligands found in the PDB database. Application of this model to our in-house library has led us to a new scaffold capable of interrupting protein-protein interactions. A synthetic library based on this and related scaffolds resulted in new classes of compounds that possess biochemical and cellular activity and good pharmacokinetic properties. We assume that such general approach to PPI inhibitors design may be useful for the development of inhibitors of various PPI types, including Bcl/XL.
['Vasilevich|Natalya I|NI|', 'Afanasyev|Ilya I|II|', 'Kovalskiy|Dmitry A|DA|', 'Genis|Dmitry V|DV|', 'Kochubey|Valery S|VS|']
D002460:Cell Line D015195:Drug Design D004353:Drug Evaluation, Preclinical D006801:Humans D008024:Ligands D008958:Models, Molecular D058990:Molecular Targeted Therapy D008970:Molecular Weight D011487:Protein Conformation D054730:Protein Interaction Domains and Motifs D051736:Proto-Oncogene Proteins c-mdm2 D054852:Small Molecule Libraries D016159:Tumor Suppressor Protein p53
protein-protein interaction drug design molecular modeling signal transduction and modulators (activation/inhibition) structure-based drug design